This course has expired. View available courses.
Cardiovascular
New, Effective Hyperkalemia Management and Enabling Optimal RAASi Therapy Patient Health Management (PHM) Program
Duration: 1.5 hr | Sponsor: Vifor Pharma
This Patient Health Management program will allow physicians to gain enhanced practical knowledge and insights into new best practices to safely and effectively manage hyperkalemia, avoiding episodic and dangerous outcomes.
Step 1: Complete the 1-hour CME course
Using patient case studies, this CME course reviews best practice scenarios for using improved potassium lowering medication regimens to decrease risk and prevent complications associated with hyperkalemia
Step 2: Physician Screening Tool
Complete a screening questionnaire to provide an overview of your practice experience and a broad picture of your current treatment approaches for hyperkalemia.
Step 3: Reflective Survey
The Reflective Survey will provide you with a brief and targeted review of the key learnings, helping you to consider how you’ve incorporated the knowledge gained over the course of the program
DURATION
1.5 hr
PROFESSION
Specialist
# OF CREDITS
0
ACCREDITATION
Unaccredited
EXPIRY DATE
2023-02-28
Duration: 1.5 hr | Sponsor: Vifor Pharma
This Patient Health Management program will allow physicians to gain enhanced practical knowledge and insights into new best practices to safely and effectively manage hyperkalemia, avoiding episodic and dangerous outcomes.
Step 1: Complete the 1-hour CME course
Using patient case studies, this CME course reviews best practice scenarios for using improved potassium lowering medication regimens to decrease risk and prevent complications associated with hyperkalemia
Step 2: Physician Screening Tool
Complete a screening questionnaire to provide an overview of your practice experience and a broad picture of your current treatment approaches for hyperkalemia.
Step 3: Reflective Survey
The Reflective Survey will provide you with a brief and targeted review of the key learnings, helping you to consider how you’ve incorporated the knowledge gained over the course of the program
This material has been developed with educational support from CSL Vifor.
Faculty
Amal Najrani, MD, MOH
Saeed Al Ahmari, MBBs, MRCP (UK)
Javed Butler, MD, MPH, MBA
David Strain, MB, ChB, BSc (Hons), MD, FRCP
Learning objectives
After completion of this PHM, participants will be better able to:
- Outline the causes of hyperkalemia, the burden of disease, and its impact of morbidity and mortality
- Describe the role potassium-binder therapy (with new agents) versus traditional therapy in the management of hyperkalemia
- Review the considerations for making treatment choices, including the benefits of maintaining optimal RAASi therapy and dosing
- Identify specific at-risk patient types and apply the latest recommendations for treatment and management of hyperkalemia